Erythropoietin regulates the proliferation and differentiation of erythroid precursor cells.
ABSTRACT
Erythropoietin regulates the proliferation and differentiation of erythroid precursor cells. Its effect is mediated by the erythropoietin receptor (EPOR), a member of a large family of cytokine receptors. The EPOR gene has recently been cloned, sequenced, and characterized. As shown experimentally, its intracellular C-terminal part contains a domain exerting negative control on erythropoiesis. Here we describe a G to A transition in nucleotide 6002 of the EPOR gene that converts a TGG codon for tryptophan into a TAG stop codon, predicting the truncation of the 70 C-terminal amino acids of the EPOR molecule. The mutation occurs in heterozygous form in the germ-line DNA of members of a large kindred in which primary erythrocytosis is segregating as a mild autosomal dominant trait. The mutation cosegregates with the disease phenotype in all 29 affected family members studied; it occurs in no unaffected family members or unrelated controls. This appears to be an example of a human condition caused by an EPOR mutation. Striking similarities exist between the human phenotype described here and phenotypes of cell lines expressing similarly truncated EPOR molecules produced experimentally. By analogy with these in vitro studies, one can hypothesize that the truncated EPOR molecules are activated by suppression of phosphorylation leading to loss of the down-modulation exerted by intact EPOR molecules. Experimental modifications of the EPOR gene may eventually have therapeutic applications.
Erythroid precursor cells are stimulated by a glycoprotein regulator, erythropoietin (EPO) , that binds to the extracellular N-terminal part of the erythropoietin receptor (EPOR). Details of the signal transduction mechanism are only partially understood. The recent cloning and characterization of the EPOR gene (1) (2) (3) (4) (5) has allowed some insight into the mechanisms by which it acts. A conserved sequence motif, Trp-Ser-Xaa-Trp-Ser, located immediately outside the transmembrane domain appears to play a critical role (6) probably affecting protein folding, ligand binding, and signal transduction (7) . As shown experimentally, the intracellular part of the EPOR molecule contains two domains with distinct functions. By generating truncated versions of the murine Epor gene and studying the EPO-dependent growth characteristics of cells transfected with these constructs, a positivecontrol domain and a negative-control domain were delineated (8, 9) . The latter is located at the 3' end of the last exon, corresponding to -40 amino acids in the C-terminal region of the molecule.
Erythrocytosis or polycythemia has numerous causes, many of which are secondary to abnormal conditions such as heart or lung disease. Even circumstances such as smoking and exposure to high altitude can induce erythrocytosis (10) . Other predisposing factors include abnormal Hb and disturbances in the metabolism of 2,3-diphosphoglycerate (11) .
Constitutively elevated levels of EPO can lead to erythrocytosis (12) .
As far as we know, no abnormal condition in humans has so far been ascribed to mutations of the EPO or EPOR genes.
We reasoned that individuals with unexplained erythrocytosis might well have an abnormality of EPOR. In particular, abnormalities affecting the negative growth-regulating domain of EPOR might lead to erythrocytosis. If the resulting clinical condition were mild enough to be compatible with normal reproduction, Mendelian inheritance might be expected. Familial erythrocytosis of unknown origin is a recognized, albeit rare, entity (11, 13, 14) .
In previous communications, we described a large kindred in which erythrocytosis is inherited as a dominant trait (15) that shows linkage to a polymorphic marker adjacent to the EPOR gene (16) . Here we describe a mutation in the C-terminal part of the EPOR gene that cosegregates with the disease phenotype in the family. We show that heterozygosity for the truncation of EPOR leads to erythrocytosis without any other phenotypic abnormalities.
MATERIALS AND METHODS
The Family. We previously described a family in which erythrocytosis is segregating (15) . Based on clinical criteria, >30 individuals are affected by the condition; all descend from a founding couple (born in 1853 and 1855), who are five generations removed from the present youngest generation (15, 16) .
The Phenotype. The clinical condition is so mild that many affected individuals are not themselves aware of any abnormality, nor do they have any sense of illness. The clinical and laboratory findings based on the study of 25 affected and 72 unaffected family members can be summarized as follows (15) 
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Analysis of in vitro erythroid colony formation by bone marrow and blood cells from affected individuals (15) showed normal or slightly increased activity in the presence of a standard concentration of exogenous EPO (1 unit/ml). However, at lower levels of EPO, cells from affected family members clearly formed more erythroid colonies than controls, especially at very low EPO levels. Notably, cells from all 3 affected family members tested formed erythroid colonies even in the absence of exogenous EPO, a phenomenon that did not occur in controls.
In summary, the condition is a marked erythrocytosis with no or slight clinical implications. Laboratory findings are compatible with the pathogenetic mechanism being an increased sensitivity to EPO by progenitor cells (15) .
For the purpose of determining the possible cosegregation of the mutation with the phenotype, the best clinical parameters are Hb content, hematocrit, and erythrocyte count. In other words, no single qualitative clinical or laboratory finding can unequivocally establish affected or unaffected status. Moreover, the quantitative parameters described above are subject to variations due to a number of physiological factors. In this study, we defined the criteria for affected status as follows: affected males, Hb 181 g/liter or higher on at least one occasion; unaffected males, Hb never 160 g/liter or higher; affected females, Hb 161 g/liter or higher on at least one occasion; unaffected females, Hb never 140 g/liter or higher. These criteria leave an intermediate group of individuals in whom affection status cannot be determined based on clinical criteria. Children have generally lower Hb values than adults and are therefore more difficult to assess. For the analysis of segregation, no individuals <17 years old were assigned any affection status.
DNA Sequencing. Using genomic sequences deposited in the GenBank data base (accession no. M60459), we designed primers to amplify the 3' region of EPOR comprising exons 7 and 8 and the intron between them (Table 1) . Direct sequencing was done essentially as described (17) . Genomic DNA derived from blood was amplified by using the primer pairs listed in Table 1 
RESULTS
Definition of Mutation. Sequencing of the region amplified by EPOR primer pair 3 revealed a G to A mutation at position 6002 in an affected family member. An unaffected family member showed only G at position 6002 (Fig. 1) . The G to A mutation at position 6002 alters the codon for amino acid 439 ofthe EPOR protein from TGG encoding tryptophan to TAG, which is a stop codon. This predicts the production of an EPOR molecule truncated for the last 70 amino acids at the C-terminal end of the molecule.
No other changes were seen in the sequences covered by EPOR primer pairs 1-3 comprising exons 7 and 8 and the intron between them. The rest ofthe gene was not sequenced, so that mutations in other parts cannot be formally excluded. Segregation of Mutation in Family. The mutation abolishes a restriction site for Nco I. In DNA without the mutation, the 333-bp fragment amplified by primer pair 3 is cut into fragments 100 and 233 bp long. After digestion with Nco I, DNA carrying the mutation in heterozygous form shows the same 2 fragments plus a 333-bp fragment (Fig. 2) . We used this assay to search for the mutation in all 60 members of the erythrocytosis family from whom samples were available (Fig. 3) . Based on clinical evidence, 29 members had been classified as affected; all 29 were heterozygous for the mutation by the Nco I assay. None of 21 clinically unaffected individuals (including 9 spouses) had the mutation. Of the 10 individuals in whom affection status could not be determined clinically, 4 had the mutation and 6 did not (Fig. 3) . Thus, there was total concordance between the mutation and the phenotype. As an indication of the significance of this association, we calculated (18) the logarithm of odds (lod) score, setting the frequency of the mutation conservatively at 0.01. The lod score at zero recombination fraction was 12.49.
Control Population. In addition to the members of the erythrocytosis family, we tested DNA from 50 randomly chosen healthy blood donors from the same district in Finland as the one where most of the family members live. None of the blood donors had the mutation. Analysis of the blood donors was done by digestion with Sty I, an enzyme that is less expensive than Nco I. The 333-bp fragment encompassing the mutation has two Sty I sites in normal DNA, creating fragments of 100, 116, and 117 bp. With the abolishment of one Sty I site at the mutation, Sty I digestion results in fragments 117 and 216 bp long. This pattern was not seen in any blood donor after amplification with primer pair EPOR3, digestion with Sty I, and resolution in 2% agarose gels as described above.
DISCUSSION
The mutation we describe gives rise to a translation termination codon, TAG. Thus, the resulting protein product is truncated for all 70 amino acids downstream of the mutation. That this defect is in turn responsible for the clinical phenotype is obvious from the cosegregation of the mutation with the phenotype in all cases and the absence of the mutation in all unaffected members of the family as well as in healthy controls. Moreover, there is a striking similarity between the truncation of EPOR caused by the mutation we describe and the experimentally produced truncation of 40 C-terminal amino acids of the murine Epor gene that was studied in an in vitro expression system (9) . The effects of the mutations are similar, too. In the affected human individuals described here, erythrocytosis leading to an increase in Hb concentration in blood and a high hematocrit value are the only phenotypic manifestations of the mutation. In vitro sensitivity of erythroid precursor cells to EPO is enhanced even to the degree that erythroid colonies arise without the addition of exogenous EPO (trace amounts occur in the medium). Accordingly, the serum concentration of EPO of these individuals is low or normal (15) . This phenotype corresponds well with that found in interleukin 3-dependent cells transfected with a truncated EPOR gene: growth occurred maximally in the presence of 1/10th the normal concentration of EPO (9) . Therefore, inasmuch as comparisons between these in vitro and in vivo phenotypes are meaningful, they are similar.
Even though constitutional mutations of the EPOR gene have not been previously described, very recent experimental evidence has begun to explain several aspects of its functioning. For instance, a point mutation converting arginine to cysteine at codon 129 in the extracellular domain of the murine Epor gene results in constitutive activation (19) , and mice infected with the altered Epor gene develop erythrocytosis (20) . It has been hypothesized that homodimerization plays a role in ligand-induced signal transduction (21) . The cytoplasmic domain of EPOR does not itself have any protein kinase motif but associates with protein kinase activity that is not yet fully characterized (22) . Lineage specificity may be determined mainly by the processing and translocation to the cell surface of the protein (23) .
Experimental evidence regarding the C-terminal end of the cytoplasmic domain is relevant to the findings presented in this paper. As stated above a positive-control domain and a negative-control domain (in the 3' end of the gene) have been proposed (8, 9) . The phosphorylation of EPOR was recently studied by immunoprecipitation and an in vitro protein kinase assay. Three abnormal EPOR molecules truncated for 42, 27, and 11 amino acids at the C-terminal end could be shown to be phosphorylated in vitro (24) , but the degree of phosphorylation was poorer when more amino acids were missing. A murine Epor mutant lacking the terminal 108 amino acids retained mitogenic activity and the ability to induce tyrosine phosphorylation (25) . These results can be interpreted to indicate that phosphorylation or interaction with a protein kinase is the mechanism by which the proliferative action of EPOR is down-modulated. Moreover, the terminal residues of the cytoplasmic domain appear to mediate a selective down-modulation of the responsiveness of target cells to granulocyte-macrophage/colony-stimulating factor (26) . The C-terminal end of EPOR may therefore also promote erythroid commitment of progenitor cells belonging to the myeloid lineage.
Splicing errors of human EPOR have been observed in a chemically treated human erythroleukemia cell line, but normal human cells did not show significant evidence of aberrant splicing (27) . A truncated molecule lacking most of the cytoplasmic region except for 56 amino acids encoded by exon 7 is prevalent in early erythroid progenitor cells, transduces a mitogenic signal, and predisposes to programmed cell death (28) . Finally, circumstantial evidence implicating the C-terminal end of EPOR in erythroleukemia was recently provided by the observation of a deletion or translocation involving the EPOR gene in a human erythroleukemia cell line (29) . In human pathology, the naturally occuffing mutation described here appears to be a fairly unique example of a mutation leading to an increased functional activity that does not have any harmful effects on its bearer. On the contrary, the resulting erythrocytosis and high Hb concentration lead to increased oxygen transport capacity. This in turn should be beneficial under several circumstances including certain diseases and many types of physical activity demanding high muscle performance. At the present time, it is not yet possible to assess whether truncation of the EPOR molecule might be exploited in therapy. Anemias, cytopenias, and other conditions with depressed erythrocyte production should be targets offuture research efforts. Of note is the fact that heterozygosity for the mutation is sufficient to bring about a phenotypic effect. In other words, even in the presence of presumably equal amounts of the normal EPOR molecule, the loss of the negative-control domain in half of the molecules overstimulates the erythroid cells significantly. We did not find any individual homozygous for the mutation so one cannot yet tell whether this might be harmful.
Familial forms of erythrocytosis of undetermined etiology are probably rare. The subject has been reviewed by several authors (11, 13, 14, 30) . A small number of large pedigrees displaying typical autosomal dominant inheritance have been described; some ofthese closely resemble the family we have studied. For instance, a two-generation family with 3 affected (13), a three-generation family with 7 affected (13) , a fourgeneration family with 13 affected (14) , and a threegeneration family with 11 affected (14) individuals have been studied. Recessive inheritance has been invoked in families with a single affected individual or in affected sibs whose parents are both normal (11, 14) . It remains to be determined whether these are true examples of recessive inheritance, as new dominant mutations or gonadal mosaicism are alternative explanations.
It may be too early to assess the frequency with which mild sporadic erythrocytosis of unknown etiology occurs because such a condition, especially if it is clinically harmless, might well be greatly underdiagnosed and underreported in the literature. The results presented in this paper should encourage investigators to search for mutations in the EPOR gene in both familial and sporadic erythrocytosis. It should not be difficult to screen many individuals with erythrocytosis for mutations of the EPOR gene. Methods presently best suited for such screening include single-strand conformation polymorphism (31) and denaturing gradient gel electrophoresis (32 
